Gujarat Kidney and Super Speciality Complete Financial Statements
In FY2026, Gujarat Kidney and Super Speciality (GKSL) reported revenue ₹31 Cr, net profit ₹5 Cr and EPS ₹0.81, with a net profit margin of 16.1% and ROE of 2.0%. Full financial statements from FY2022 to FY2026 (5 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Examine GKSL Q4 results for recent quarterly revenue, profit and EPS trends.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
GKSL Revenue, Net Profit & EBITDA — Year-on-Year Growth
GKSL YoY (Mar 2025 vs Mar 2026) — revenue +210.0%, net profit +400.0%, EBITDA +133.3%, expenses +242.9%. For live price, earnings ratios and company overview, see Gujarat Kidney and Super Speci stock price NSE.
GKSL Income Statement — Revenue, EBITDA & Net Profit
Gujarat Kidney and Super Speciality revenue ₹31 Cr, EBITDA ₹7 Cr, net profit ₹5 Cr, EPS ₹0.81 (2026) — net profit margin 16.1%. Analyse GKSL FII DII holdings to track promoter, FII and institutional holdings.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 31 | 13 | 10 | 15 | 23 | 9 | 12 |
| Expenses | 24 | 8 | 7 | 7 | 16 | 5 | 7 |
| EBITDA | 7 | 5 | 3 | 9 | 7 | 5 | 5 |
| Operating Profit Margin % | 21.00% | 40.00% | 27.00% | 57.00% | 30.00% | 52.00% | 39.00% |
| Depreciation | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Profit Before Tax | 5 | 4 | 2 | 8 | 5 | 4 | 4 |
| Tax | 0 | 1 | 0 | 2 | 1 | 1 | 1 |
| Net Profit | 5 | 3 | 1 | 5 | 4 | 3 | 3 |
| Earnings Per Share (₹) | 0.81 | 0.47 | 0.25 | 0.85 | 0.52 | 0.65 | 0.52 |
GKSL Balance Sheet — Assets, Liabilities & Shareholders' Equity
GKSL total assets ₹298 Cr, total equity ₹253 Cr, total liabilities ₹ Cr (2026) — ROE 2.0%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| ASSETS | |||||
| Total Assets | 298 | 55 | 21 | 4 | 4 |
| Current Assets | 105 | 22 | 7 | 1 | 1 |
| Fixed Assets | 38 | 31 | 14 | 0 | 3 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 |
| Investments | 2 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 24 | 7 | 4 | 1 |
| LIABILITIES | |||||
| Total Liabilities | |||||
| Current Liabilities | 15 | 7 | 6 | 0 | 0 |
| Non-Current Liabilities | |||||
| SHAREHOLDERS' EQUITY | |||||
| Total Equity | 253 | 27 | 11 | 0 | 0 |
| Share Capital | 16 | 11 | 0 | 0 | 0 |
| Reserves & Surplus | 237 | 15 | 2 | 0 | 0 |
GKSL Cash Flow Statement — Operating, Investing & Financing
Gujarat Kidney and Super Speciality operating cash flow ₹14 Cr, investing ₹-18 Cr, financing ₹6 Cr, net cash flow ₹2 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 |
|---|---|---|---|
| Operating Activities | 14 | 1 | 0 |
| Investing Activities | -18 | 0 | 0 |
| Financing Activities | 6 | -1 | 0 |
| Net Cash Flow | 2 | 1 | 0 |